|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Heinzerling, Lucie; Eigentler, Thomas K.; Fluck, Michael; Hassel, Jessica C.; Heller-Schenck, Daniela; Leipe, Jan; Pauschinger, Matthias; Vogel, Arndt; Zimmer, Lisa und Gutzmer, Ralf
(2019):
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.
In: Esmo Open, Bd. 4, Nr. 3, UNSP e000491
Huebner, Jutta; Mohr, Peter; Simon, Jan-Christoph; Fluck, Michael; Berking, Carola; Zimmer, Lisa und Loquai, Carmen
(2016):
Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial.
In: Journal Der Deutschen Dermatologischen Gesellschaft, Bd. 14, Nr. 5: S. 508-513
Zimmer, Lisa; Eigentler, Thomas K.; Kiecker, Felix; Simon, Jan; Utikal, Jochen; Mohr, Peter; Berking, Carola; Kaempgen, Eckhart; Dippel, Edgar; Stadler, Rudolf; Hauschild, Axel; Fluck, Michael; Terheyden, Patrick; Rompel, Rainer; Loquai, Carmen; Assi, Zeinab; Garbe, Claus und Schadendorf, Dirk
(2015):
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
In: Journal of Translational Medicine
13:351
[PDF, 1MB]
Voskens, Caroline J.; Goldinger, Simone M.; Loquai, Carmen; Robert, Caroline; Kaehler, Katharina C.; Berking, Carola; Bergmann, Tanja; Bockmeyer, Clemens L.; Eigentler, Thomas; Fluck, Michael; Garbe, Claus; Gutzmer, Ralf; Grabbe, Stephan; Hauschild, Axel; Hein, Rüdiger; Hundorfean, Gheorghe; Justich, Armin; Keller, Ullrich; Klein, Christina; Mateus, Christine; Mohr, Peter; Paetzold, Sylvie; Satzger, Imke; Schadendorf, Dirk; Schlaeppi, Marc; Schuler, Gerold; Schuler-Thurner, Beatrice; Trefzer, Uwe; Ulrich, Jens; Vaubel, Julia; Moos, Roger von; Weder, Patrik; Wilhelm, Tabea; Göppner, Daniela; Dummer, Reinhard und Heinzerling, Lucie M.
(2013):
The price of tumor control. An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
In: PLOS ONE 8(1), e53745 [PDF, 5MB]
In: PLOS ONE 8(1), e53745 [PDF, 5MB]